Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 9/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPA3 | P15088 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2559773 | 1.00 | GAA (0.50) | GAAMAPTMMENPC1RAB9A | |
| SCHEMBL5507068 | 0.85 | NPC1 (0.49) | MMENPC1RAB9AFOLH1 | |
| SCHEMBL7211707 | 0.85 | MME (0.51) | MMENPC1RAB9A | |
| SCHEMBL6130477 | 0.85 | MME (0.51) | MMENPC1RAB9A | |
| SCHEMBL5507066 | 0.85 | NPC1 (0.49) | MMENPC1RAB9AFOLH1 | |
| SCHEMBL7004556 | 0.85 | NPC1 (0.49) | MMENPC1RAB9AFOLH1 | |
| SCHEMBL6130478 | 0.85 | MME (0.51) | MMENPC1RAB9A | |
| SCHEMBL10610612 | 0.84 | FOLH1 (0.60) | GAAMMENPC1RAB9ACPA3 | |
| SCHEMBL6343393 | 0.84 | FOLH1 (0.60) | GAAMMENPC1RAB9ACPA3 | |
| SCHEMBL8078091 | 0.82 | ACE (0.56) | MMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019182549-A1 | PRIMARY METHODS AND PROCESSES FOR LIFE EXTENSION IN MODERN-DAY HUMANS | POSTREL RICHARD (US) | 2019-09-26 | — | — | WO | claimed |
| CN-101497584-B | Isoquinoline-3-formyl amino acid formyl amino acid benzyl ester, as well as preparation and use thereof | UNIV CAPITAL MEDICAL | 2010-12-22 | — | — | CN | claimed |
| CN-101497584-A | Isoquinoline-3-formyl amino acid formyl amino acid benzyl ester, as well as preparation and use thereof | UNIV CAPITAL MEDICAL (CN) | 2009-08-05 | — | — | CN | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023023538-A2 | TREATING TISSUE INFLAMMATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2020028515-A1 | NEUROPROTECTIVE DISRUPTION OF KV2.1/SYNTAXIN INTERACTION BY SMALL MOLECULES | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2019182549-A1 | PRIMARY METHODS AND PROCESSES FOR LIFE EXTENSION IN MODERN-DAY HUMANS | POSTREL RICHARD (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-2954055-A2 | CELL LINES FOR VIRUS PRODUCTION AND METHODS OF USE | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-1397370-B1 | BETA-BENZYLOXYASPARTATE DERIVATIVES WITH AMINO GROUP ON BENZENE RING | SUNTORY HOLDINGS LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-2560687-A2 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | Nlife Therapeutics S.L. (ES) | 2013-02-27 | — | — | EP | disclosed |
| EP-2558439-A1 | A PROCESS FOR THE PREPARATION OF ISOSERINE DERIVATIVES | Indena S.p.A. (IT) | 2013-02-20 | — | — | EP | disclosed |
| US-7247652-B2 | β-benzyloxyaspartate derivatives with amino group on benzene ring | SUNTORY LIMITED (JP) | 2007-07-24 | — | — | US | disclosed |
| WO-2006062683-A2 | TREATMENT AND PREVENTION OF EPILEPSY | UNIVERSITY OF ROCHESTER (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006037569-A1 | PROTEIN ASSAY OF TYPE EAAC1 | IONGATE BIOSCIENCES GMBH (DE) | 2006-04-13 | — | — | WO | disclosed |
| EP-1628951-A1 | (BETA)-BENZYLOXYASPARTATE DERIVATIVES WITH PHOTOSENSITIVE GROUPS | SUNTORY LIMITED (JP) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004106286-A1 | β-BENZYLOXYASPARTATE DERIVATIVES WITH PHOTOSENSITIVE GROUPS | SUNTORY LIMITED (JP) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242652-A1 | Beta benzyloxyaspartate derivatives with amino group on benzene ring | SUNTORY HOLDINGS LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20040242652-A1 | Beta benzyloxyaspartate derivatives with amino group on benzene ring | SUNTORY HOLDINGS LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1397370-A1 | B-BENZYLOXYASPARTATE DERIVATIVES WITH AMINO GROUP ON BENZENE RING | SUNTORY LIMITED (JP) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003000698-A1 | β-BENZYLOXYASPARTATE DERIVATIVES WITH AMINO GROUP ON BENZENE RING | SUNTORY LIMITED (JP) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242652-A1 | Beta benzyloxyaspartate derivatives with amino group on benzene ring | SLC1A5, SLC1A1, SLC7A1 | GAA 1564/4885MAPT 2413/4885MME 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.